238 related articles for article (PubMed ID: 25304930)
1. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.
Wilson C; Lin JE; Li P; Snook AE; Gong J; Sato T; Liu C; Girondo MA; Rui H; Hyslop T; Waldman SA
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2328-37. PubMed ID: 25304930
[TBL] [Abstract][Full Text] [Related]
2. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis.
Lin JE; Colon-Gonzalez F; Blomain E; Kim GW; Aing A; Stoecker B; Rock J; Snook AE; Zhan T; Hyslop TM; Tomczak M; Blumberg RS; Waldman SA
Cancer Res; 2016 Jan; 76(2):339-46. PubMed ID: 26773096
[TBL] [Abstract][Full Text] [Related]
3. APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis.
Blomain ES; Rappaport JA; Pattison AM; Bashir B; Caparosa E; Stem J; Snook AE; Waldman SA
Cancer Biol Ther; 2020 May; 21(5):441-451. PubMed ID: 32037952
[TBL] [Abstract][Full Text] [Related]
4. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.
Gibbons AV; Lin JE; Kim GW; Marszalowicz GP; Li P; Stoecker BA; Blomain ES; Rattan S; Snook AE; Schulz S; Waldman SA
Cancer Res; 2013 Nov; 73(22):6654-66. PubMed ID: 24085786
[TBL] [Abstract][Full Text] [Related]
5. Guanylyl cyclase C signaling axis and colon cancer prevention.
Pattison AM; Merlino DJ; Blomain ES; Waldman SA
World J Gastroenterol; 2016 Sep; 22(36):8070-7. PubMed ID: 27688649
[TBL] [Abstract][Full Text] [Related]
6. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
Li P; Wuthrick E; Rappaport JA; Kraft C; Lin JE; Marszalowicz G; Snook AE; Zhan T; Hyslop TM; Waldman SA
Cancer Res; 2017 Sep; 77(18):5095-5106. PubMed ID: 28916678
[TBL] [Abstract][Full Text] [Related]
7. GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?
Li P; Lin JE; Marszlowicz GP; Valentino MA; Chang C; Schulz S; Pitari GM; Waldman SA
Drug News Perspect; 2009; 22(6):313-8. PubMed ID: 19771320
[TBL] [Abstract][Full Text] [Related]
8. Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer.
Blomain ES; Merlino DJ; Pattison AM; Snook AE; Waldman SA
Mol Pharmacol; 2016 Sep; 90(3):199-204. PubMed ID: 27251363
[TBL] [Abstract][Full Text] [Related]
9. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention.
Yarla NS; Gali H; Pathuri G; Smriti S; Farooqui M; Panneerselvam J; Kumar G; Madka V; Rao CV
Semin Cancer Biol; 2019 Jun; 56():168-174. PubMed ID: 30189250
[TBL] [Abstract][Full Text] [Related]
10. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.
Lin JE; Li P; Snook AE; Schulz S; Dasgupta A; Hyslop TM; Gibbons AV; Marszlowicz G; Pitari GM; Waldman SA
Gastroenterology; 2010 Jan; 138(1):241-54. PubMed ID: 19737566
[TBL] [Abstract][Full Text] [Related]
11. Can colorectal cancer be prevented or treated by oral hormone replacement therapy?
Li P; Lin JE; Schulz S; Pitari GM; Waldman SA
Curr Mol Pharmacol; 2009 Nov; 2(3):285-92. PubMed ID: 20021465
[TBL] [Abstract][Full Text] [Related]
12. Silencing the intestinal GUCY2C tumor suppressor axis requires
Pattison AM; Barton JR; Entezari AA; Zalewski A; Rappaport JA; Snook AE; Waldman SA
Cancer Biol Ther; 2020 Sep; 21(9):799-805. PubMed ID: 32594830
[TBL] [Abstract][Full Text] [Related]
13. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.
Weinberg DS; Lin JE; Foster NR; Della'Zanna G; Umar A; Seisler D; Kraft WK; Kastenberg DM; Katz LC; Limburg PJ; Waldman SA
Cancer Prev Res (Phila); 2017 Jun; 10(6):345-354. PubMed ID: 28396341
[TBL] [Abstract][Full Text] [Related]
14. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice.
Valentino MA; Lin JE; Snook AE; Li P; Kim GW; Marszalowicz G; Magee MS; Hyslop T; Schulz S; Waldman SA
J Clin Invest; 2011 Sep; 121(9):3578-88. PubMed ID: 21865642
[TBL] [Abstract][Full Text] [Related]
15. Guanylate cyclase C deficiency causes severe inflammation in a murine model of spontaneous colitis.
Harmel-Laws E; Mann EA; Cohen MB; Steinbrecher KA
PLoS One; 2013; 8(11):e79180. PubMed ID: 24244444
[TBL] [Abstract][Full Text] [Related]
16. Guanylin hormone loss could trigger colon cancer.
Tanday S
Lancet Oncol; 2014 Nov; 15(12):e537. PubMed ID: 25602115
[No Abstract] [Full Text] [Related]
17. Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia.
Bashir B; Merlino DJ; Rappaport JA; Gnass E; Palazzo JP; Feng Y; Fearon ER; Snook AE; Waldman SA
Hum Pathol; 2019 May; 87():103-114. PubMed ID: 30716341
[TBL] [Abstract][Full Text] [Related]
18. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Aka AA; Rappaport JA; Pattison AM; Sato T; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2017 May; 10(5):549-557. PubMed ID: 28162021
[TBL] [Abstract][Full Text] [Related]
19. GUCY2C ligand replacement to prevent colorectal cancer.
Blomain ES; Pattison AM; Waldman SA
Cancer Biol Ther; 2016 Jul; 17(7):713-8. PubMed ID: 27104761
[TBL] [Abstract][Full Text] [Related]
20. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
Waldman SA; Hyslop T; Schulz S; Barkun A; Nielsen K; Haaf J; Bonaccorso C; Li Y; Weinberg DS
JAMA; 2009 Feb; 301(7):745-52. PubMed ID: 19224751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
